Christine Mau

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial

Volkmar Müller, Stephan Gade, Bettina Steinbach et al. · Breast Cancer Research and Treatment · 2014 · 121 citations

Medicine, Cancer Biology, Oncology +16

Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma

Sibylle Loibl, Cristina Volz, Christine Mau et al. · Breast Cancer Research and Treatment · 2014 · 115 citations · Full text

Medicine, Oncology, Surgery +14

Prognostic evaluation of re-resection for recurrent glioblastoma using the novel RANO classification for extent of resection: A report of the RANO <i>resect</i> group

Philipp Karschnia, Antonio Dono, Jacob S. Young et al. · Neuro-Oncology · 2023 · 93 citations · Full text

Medicine, Oncology, Surgery +16

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44)

Jens Huober, Peter A. Fasching, Claus Hanusch et al. · European Journal of Cancer · 2013 · 79 citations

Medicine, Oncology, Pharmacology +15